Literature DB >> 11556855

Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma.

C Y Fan1, M F Melhem, A S Hosal, J R Grandis, E L Barnes.   

Abstract

BACKGROUND: Salivary duct carcinoma (SDC) is a rare, highly aggressive neoplasm that primarily affects the major salivary glands. It is a distinct clinicopathological entity characterized by its morphologic resemblance to ductal carcinoma of the breast, a high incidence of regional lymph node metastasis, and distant dissemination. Frequent expression of androgen receptor (AR) but not estrogen receptor or progesterone receptor in SDCs suggests that SDC bears a close immunophenotypic homology with prostatic carcinoma. An AR-mediated autocrine growth pathway consisting of epidermal growth factor receptor (EGFR) and its ligand, transforming growth factor alpha (TGF-alpha), has been implicated in the carcinogenesis of prostatic carcinoma. Androgens, in the presence of AR, mediate their mitogenic effects on prostatic cancer cells by up-regulating the transcriptional and translational activities of EGFR and TGF-alpha. Through an autocrine mode of action, TGF-alpha produced in the tumor cells binds to its receptor, EGFR, which is also expressed by these cells, resulting in a proliferative response.
OBJECTIVE: To investigate whether a TGF-alpha/EGFR autocrine pathway is present in SDCs.
DESIGN: Retrospective analysis of the expression of AR, EGFR, and TGF-alpha in 12 SDCs.
SETTING: An academic medical center.
RESULTS: Salivary duct carcinoma expresses AR, TGF-alpha, and EGFR in 11 (92%), 8 (67%), and 11 (92%) of 12 cases, respectively.
CONCLUSION: An AR-mediated TGF-alpha/EGFR autocrine pathway may be implicated in the tumorigenesis of SDC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556855     DOI: 10.1001/archotol.127.9.1075

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  18 in total

Review 1.  Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification.

Authors:  Roderick H W Simpson
Journal:  Head Neck Pathol       Date:  2013-07-03

2.  Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.

Authors:  Michelle D Williams; Dianna B Roberts; Merrill S Kies; Li Mao; Randal S Weber; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

3.  Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.

Authors:  Kenta Kawahara; Akimitsu Hiraki; Ryoji Yoshida; Hidetaka Arita; Yuichiro Matsuoka; Toshio Yamashita; Kan-Ichi Koga; Masashi Nagata; Akiyuki Hirosue; Daiki Fukuma; Hideki Nakayama
Journal:  Mol Clin Oncol       Date:  2017-04-21

4.  [Primary ductal adenocarcinoma near the orbit].

Authors:  M Grünbaum; J Ervens; H Stein; C Loddenkemper
Journal:  Pathologe       Date:  2010-07       Impact factor: 1.011

5.  Salivary type tumors seen in consultation.

Authors:  Simion I Chiosea; Robert Peel; E Leon Barnes; Raja R Seethala
Journal:  Virchows Arch       Date:  2009-03-07       Impact factor: 4.064

6.  Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumors.

Authors:  Nikolaos G Nikitakis; Mark A Scheper; Vasileios S Papanikolaou; Alexandra Sklavounou; John J Sauk
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-03-09

Review 7.  Molecular Pathology and Biomarkers.

Authors:  Patrick K Ha; Göran Stenman
Journal:  Adv Otorhinolaryngol       Date:  2016-04-12

8.  An immunohistochemical panel for reliable differentiation of salivary duct carcinoma and mucoepidermoid carcinoma.

Authors:  Randall T Butler; Matthew E Spector; Dafydd Thomas; Andrew S McDaniel; Jonathan B McHugh
Journal:  Head Neck Pathol       Date:  2013-09-25

Review 9.  Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.

Authors:  Nicole C Schmitt; Hyunseok Kang; Arun Sharma
Journal:  Oral Oncol       Date:  2017-09-21       Impact factor: 5.337

Review 10.  Systemic therapy in the management of metastatic or advanced salivary gland cancers.

Authors:  Aymen Lagha; Nesrine Chraiet; Mouna Ayadi; Sarra Krimi; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Journal:  Head Neck Oncol       Date:  2012-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.